eligibility_summary
Adults (>18) with multiple myeloma seen at Duke who started BLENREP for relapsed/refractory disease between Aug 5, 2020 and Nov 22, 2022, with at least 1 month of care at Duke Cancer Institute after starting. Exclude: anyone in BLENREP clinical trials (including expanded access) and those >89 years old at therapy start.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Belantamab mafodotin-blmf (Blenrep) — an antibody-drug conjugate (ADC) consisting of an anti-BCMA IgG1 monoclonal antibody linked to the microtubule inhibitor monomethyl auristatin F (MMAF). Mechanism of action: binds B-cell maturation antigen (BCMA) on malignant plasma cells, is internalized, and releases MMAF to disrupt microtubules and trigger apoptosis, the antibody’s Fc region can also drive immune-mediated killing (ADCC/ADCP). Targets: BCMA-expressing myeloma/plasma cells, microtubule cytoskeleton, BCMA signaling axis. Study type/purpose: observational, real-world analysis of care patterns, dosing/adjustments, eye-care visits, healthcare use, and outcomes in RRMM patients treated with Blenrep at Duke.